Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies
This analysis did not identify evidence of negative effects on cognition following short-term or long-term maintenance treatment with ESK+OAD in patients with TRD.
Authors
- Rachel Ochs-Ross
- Jaskaran Singh (ORCID: https://orcid.org/0000-0001-8466-0994)
- Wayne C. Drevets (ORCID: https://orcid.org/0000-0002-5097-3930)
- Randall L. Morrison
- Gerard Sanacora (ORCID: https://orcid.org/0000-0003-3722-8829)
- Paul Maruff (ORCID: https://orcid.org/0000-0002-6947-9537)
- Ella Daly (ORCID: https://orcid.org/0000-0001-8380-1249)
- Rosanne Lane
- Keith Karcher
- Maggie Fedgchin
- Kim Cooper
Institutions
- Yale University (US)
- Janssen (United States) (US)
- The Prostate Centre (GB)
Publication Details
- Journal
- The International Journal of Neuropsychopharmacology
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1093/ijnp/pyae046
- Citations
- 7
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 3.13
Funders
- Yale University
- Gilead Sciences
- Usona Institute
- European College of Neuropsychopharmacology
- Janssen Research and Development